0

ALOXI از شرکت HELSINN HLTHCARE

تصویر پیدا نشد !

اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA) استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است

ALOXI از شرکت HELSINN HLTHCARE

New Drug Application (NDA): 021372

Company: HELSINN HLTHCARE

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
ALOXI PALONOSETRON HYDROCHLORIDE EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) INJECTABLE;INTRAVENOUS Discontinued

None

Yes No
ALOXI PALONOSETRON HYDROCHLORIDE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) INJECTABLE;INTRAVENOUS Discontinued

None

Yes No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
07/25/2003 ORIG-1 Approval

Type 1 – New Molecular Entity

STANDARD

Label (PDF)

Letter (PDF)

Review

https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21372_aloxi_lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21372ltr.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-372_Alox.cfm

Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
04/01/2020 SUPPL-21 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021372s021lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021372Orig1s021, 022233Orig1s006ltr.pdf

09/18/2014 SUPPL-20 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s020lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021372Orig1s020ltr.pdf

05/27/2014 SUPPL-19 Efficacy-Pediatric

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s018s019lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021372Orig1s018,s019ltr.pdf

05/27/2014 SUPPL-18 Efficacy-Pediatric

Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021372Orig1s018,s019ltr.pdf

02/06/2014 SUPPL-17 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s017lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021372Orig1s017ltr.pdf

02/29/2008 SUPPL-10 Efficacy-Labeling Change With Clinical Data

Label (PDF)

Letter (PDF)

Review

Summary Review (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021372s008, s010ltr.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010TOC.cfm

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010_SumR.pdf

02/29/2008 SUPPL-8 Efficacy-New Indication

Label (PDF)

Letter (PDF)

Review

Summary Review (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021372s008, s010ltr.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010TOC.cfm

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021372s008s010_SumR.pdf

08/30/2007 SUPPL-6 Efficacy-New Dosing Regimen

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021372s006lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021372s006ltr.pdf

08/23/2006 SUPPL-5 Labeling

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021372s005lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021372s005ltr.pdf

07/05/2005 SUPPL-2 Labeling

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021372s002lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021372s002ltr.pdf

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
04/01/2020 SUPPL-21

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021372s021lbl.pdf
09/18/2014 SUPPL-20

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s020lbl.pdf
05/27/2014 SUPPL-19

Efficacy-Pediatric

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s018s019lbl.pdf
02/06/2014 SUPPL-17

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s017lbl.pdf
02/29/2008 SUPPL-10

Efficacy-Labeling Change With Clinical Data

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf
02/29/2008 SUPPL-8

Efficacy-New Indication

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf
08/30/2007 SUPPL-6

Efficacy-New Dosing Regimen

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021372s006lbl.pdf
08/23/2006 SUPPL-5

Labeling

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021372s005lbl.pdf
07/05/2005 SUPPL-2

Labeling

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021372s002lbl.pdf
07/25/2003 ORIG-1 Approval

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21372_aloxi_lbl.pdf
بخوانید  CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE از شرکت PAR PHARM
برچسب‌ها:

نظرات کاربران